Capitol Perspectives

  1. Arbitration For Pharmaceuticals?

    The concept known as “arbitration” to resolve billing disputes between out-of-network providers and insurers on surprise medical bills could spell doom for the pharmaceutical industry if it is cross-walked into the prescription-drug debate.

  2. Restructuring Of Medicare Part D Imminent

    New challenges have emerged regarding Medicare Part D which require a fundamental re-examination and modernization of the program.

  3. Fiscal And Monetary Policy Puts America At Risk

    A plethora of proposals are currently under consideration to wring resources out of the pharmaceutical industry, but no amount of money extracted from the life sciences sector can right-size the fundamental imbalance between the federal government’s financial obligations and taxpayers resources to finance those promises.

  4. Rebate Rule Pends As Congress Begins Moving Rx Bills

    What is the policy problem driving the populist agenda to slash pharmaceutical spending? Answer: Rising list prices and patient out-of-pocket spending.

  5. Countering Provider Consolidation

    As Congress debates partisan issues such as “Medicare for All” where private health insurance would be outlawed, troubling trends are emerging on healthcare provider consolidation that are driving up costs.

  6. Congress Scrutinizes Rx Pricing As Administration Releases Proposal To Ban Rebates

    Despite mounting evidence that pharma costs have flattened recently, the industry, during recent hearings, took licks from members on both side of the aisle in the divided Congress.

  7. New Congress Wrestles With ACA And Budget Challenges: Rich Universities A Funding Source?

    The 116th Congress convened under the shadow of a partial government shutdown with Republicans handing the gavel to newly elected Speaker Nancy Pelosi (D-CA). House Democrats have made it clear that healthcare will be a key priority, second only to investigating the Trump administration.

  8. Rx Industry Under Multifront Siege

    The latest regulatory salvo from the Trump administration on Medicare Part D and the Democratic takeover of the House of Representatives has the pharmaceutical industry scrambling to fight a multifront war to defend market-based pricing in the United States.

  9. Trump Administration Would Import Foreign Price Controls

    Two weeks before the midterm election, the Trump administration announced a sweeping plan to subject physician-administered drugs in Medicare Part B to foreign price controls. The ANPR “demonstration project” would subject half of the country to the mandatory pricing scheme but will ripple through the entire Medicare program.

  10. Told You So! Repeal Of Individual Mandate Penalty Has No Impact

    “Despite predictions that our actions would increase rates and destabilize markets, the opposite has happened,” says CMS Administrator Seema Verma.